Anandamide-derived prostamide F2α negatively regulates adipogenesis

Area of Science:

• Endocrinology
• Lipid Metabolism
• Cell Biology

Background:

• Lipid mediators play diverse roles in adipocyte differentiation.
• Anandamide promotes adipogenesis via CB1 receptors and PPARγ.
• Prostaglandin F2α ethanolamide (PGF2αEA), a derivative of anandamide, acts through specific prostaglandin F2α receptor (FP) variants.

Purpose of the Study:

• To investigate the presence and function of prostamide signaling in preadipocytes.
• To determine if prostamide signaling regulates adipogenesis.
• To elucidate the role of PGF2αEA in adipocyte differentiation.

Main Methods:

• Exposure of mouse 3T3-L1 and human preadipocytes to PGF2αEA and bimatoprost during differentiation.
• Measurement of PGF2αEA production in preadipocytes and adipocytes.
• Pharmacological antagonism of PGF2αEA receptors and inhibition of ERK1/2 phosphorylation.
• Assessment of adipogenesis in high-fat diet-fed mice and zebrafish larvae.

Main Results:

• PGF2αEA and bimatoprost inhibit adipogenesis in preadipocytes.
• PGF2αEA is produced in preadipocytes, with reduced levels in differentiating adipocytes.
• Selective antagonism of PGF2αEA receptors and ERK1/2 inhibition counteract the anti-adipogenic effects.
• Inhibition of PGF2αEA biosynthesis accelerates adipogenesis.
• Prostamide signaling inhibits adipogenesis in vivo in mice and zebrafish.

Conclusions:

• Prostamide signaling, mediated by PGF2αEA, is an anti-adipogenic mechanism in preadipocytes.
• This pathway is derived from anandamide and involves specific FP receptor variants.
• PGF2αEA levels are decreased in conditions requiring increased adipogenesis, such as high-fat diet.
• Prostamide signaling represents a novel target for modulating adipogenesis.